HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019

dc.contributor.authorBruni, Laia
dc.contributor.authorSaura Lázaro, Anna
dc.contributor.authorMontoliu, Alexandra
dc.contributor.authorBrotons, Maria
dc.contributor.authorAlemany i Vilches, Laia
dc.contributor.authorDiallo, Mamadou Saliou
dc.contributor.authorAfsar, Oya Zeren
dc.contributor.authorLamontagne, D. Scott
dc.contributor.authorMosina, Liudmila
dc.contributor.authorContreras, Marcela
dc.contributor.authorVelandia González, Martha
dc.contributor.authorPastore, Roberta
dc.contributor.authorGacic Dobo, Marta
dc.contributor.authorBloem, Paul
dc.date.accessioned2021-04-29T13:38:46Z
dc.date.available2021-04-29T13:38:46Z
dc.date.issued2021-03-01
dc.date.updated2021-04-29T09:45:41Z
dc.description.abstractWHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently approved global strategy for cervical cancer elimination as a public health problem. As of June 2020, 107 (55%) of the 194 WHO Member States have introduced HPV vaccination. The Americas and Europe are by far the WHO regions with the most introductions, 85% and 77% of their countries having already introduced respectively. A record number of introductions was observed in 2019, most of which in low- and middle- income countries (LMIC) where access has been limited. Programs had an average performance coverage of around 67% for the first dose and 53% for the final dose of HPV. LMICs performed on average better than high- income countries for the first dose, but worse for the last dose due to higher dropout. Only 5 (6%) countries achieved coverages with the final dose of more than 90%, 22 countries (21%) achieved coverages of 75% or higher while 35 (40%) had a final dose coverage of 50% or less. When expressed as world population coverage (i.e., weighted by population size), global coverage of the final HPV dose for 2019 is estimated at 15%. There is a long way to go to meet the 2030 elimination target of 90%. In the post-COVID era attention should be paid to maintain the pace of introductions, specially ensuring the most populous countries introduce, and further improving program performance globally.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid33388322
dc.identifier.urihttps://hdl.handle.net/2445/176791
dc.language.isoeng
dc.publisherElsevier B. V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.ypmed.2020.106399
dc.relation.ispartofPreventive Medicine, 2021, vol. 144
dc.relation.urihttps://doi.org/10.1016/j.ypmed.2020.106399
dc.rightscc by-nc-nd (c) Bruni et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer de coll uterí
dc.subject.classificationVacuna del papil·lomavirus
dc.subject.otherCervix cancer
dc.subject.otherPapillomavirus vaccines
dc.titleHPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
1-s2.0-S0091743520304308-main.pdf
Mida:
8.06 MB
Format:
Adobe Portable Document Format